BioVex Garners $30,000,000 Series F Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ffb186d1-ab19-4295-9783-f0ee4d4c8c77&Preview=1 -
Date
11/10/2009 -
Company Name
BioVex -
Mailing Address
34 Commerce Way Woburn, MA 01801 -
Company Description
The Company is developing a new class of potent biologics for the treatment
of cancer and prevention of infectious disease. -
Website
http://www.biovex.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Series F -
Proceeds Purposes
The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities. -
M&A Terms
-
Venture Investor
Morningside Group -
Venture Investor
Ventech -
Venture Investor
MVM Life Science Partners -
Venture Investor
Undisclosed
